Compare OABI & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OABI | MGTX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 773.1M | 881.7M |
| IPO Year | 2021 | 2018 |
| Metric | OABI | MGTX |
|---|---|---|
| Price | $4.66 | $8.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $8.33 | ★ $27.75 |
| AVG Volume (30 Days) | ★ 1.3M | 563.9K |
| Earning Date | 10-30-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.56 | ★ 33.02 |
| EPS | N/A | ★ 0.68 |
| Revenue | $18,666,000.00 | ★ $81,391,000.00 |
| Revenue This Year | $94.10 | $309.55 |
| Revenue Next Year | $30.33 | N/A |
| P/E Ratio | ★ N/A | $11.98 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $1.35 | $6.62 |
| 52 Week High | $5.45 | $15.35 |
| Indicator | OABI | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 33.45 |
| Support Level | $4.53 | $6.93 |
| Resistance Level | $5.43 | $10.08 |
| Average True Range (ATR) | 0.32 | 0.53 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 4.76 | 7.34 |
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.